Physician profile
Robert R Morgan
NPI 1508027343
$5,227.99
in general payments reported to CMS, 2019-2025
26 companies · $722 in 2025
The $722 reported for 2025 was more than what 86% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $737 · 2020: $395 · 2021: $1,118 · 2022: $870 · 2023: $636 · 2024: $751 · 2025: $722.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,108.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $1,265.60 | 2019-2025 | Cequa |
| Oyster Point Pharma, INC. | $409.72 | 2022-2025 | Tyrvaya |
| Mallinckrodt Hospital Products INC. | $382.98 | 2021-2025 | Acthar |
| Kala Pharmaceuticals, INC. | $370.61 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $361.89 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Tarsus Pharmaceuticals, INC. | $306.59 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $281.93 | 2020-2023 | |
| Allergan, INC. | $258.15 | 2019-2022 | |
| Glaukos Corporation | $238.26 | 2020-2025 | Idose, Idosetr |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $233.64 | 2019-2021 | |
| Abbvie INC. | $195.84 | 2022-2025 | |
| Alcon Vision LLC | $127.19 | 2020-2025 | Rocklatan |
| Johnson & Johnson Vision Care, INC. | $115.20 | 2019 | |
| Amgen INC. | $110.45 | 2024-2025 | Tepezza |
| Biotissue Holdings INC. | $108.29 | 2019-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $102.57 | 2024 | Iheezo |
| Dompe US, INC. | $88.60 | 2021-2025 | Oxervate |
| Shire North American Group INC | $65.21 | 2019 | |
| Thea Pharma INC. | $60.98 | 2023-2024 | Iyuzeh |
| Eyevance Pharmaceuticals LLC | $35.93 | 2021-2022 | |
| Sight Sciences, INC. | $26.11 | 2025 | Tearcare System |
| Carl Zeiss Meditec, INC. | $22.22 | 2019 | |
| Rxsight INC | $17.46 | 2022 | |
| Aerie Pharmaceuticals, INC. | $17.06 | 2019 | |
| Horizon Therapeutics Plc | $14.97 | 2023 | Tepezza |
| Ivantis, INC | $10.54 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Morgan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.